Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease
- 29 August 2007
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Biological Therapy
- Vol. 7 (9) , 1471-1480
- https://doi.org/10.1517/14712598.7.9.1471
Abstract
Respiratory syncytial virus (RSV) is a significant pathogen for infants and children with congenital heart disease. Non-sustained immunity and failure to develop an effective vaccine has steered RSV management toward a passive immunotherapy strategy in at-risk children. Palivizumab is a humanized murine monoclonal antibody targeting the RSV envelope F glycoprotein. In a Phase III clinical trial palivizumab significantly reduced RSV hospitalization in children with significant congenital heart disease and was proven to be safe. Palivizumab is one of the first monoclonal antibodies to significantly impact a pediatric disease.Keywords
This publication has 61 references indexed in Scilit:
- T Helper 1/T Helper 2 Cytokine Imbalance in Respiratory Syncytial Virus Infection Is Associated With Increased Endogenous Plasma CortisolPediatrics, 2006
- Acute and long-term effects of infection by the respiratory syncytial virus in children with congenital cardiac malformationsCardiology in the Young, 2005
- Predisposition of infants with chronic lung disease to respiratory syncytial virus-induced respiratory failure: a vascular hypothesisThe Pediatric Infectious Disease Journal, 2004
- Type 1 and Type 2 Cytokine Imbalance in Acute Respiratory Syncytial Virus BronchiolitisAmerican Journal of Respiratory and Critical Care Medicine, 2003
- Macrophage Inflammatory Protein–1α (Not T Helper Type 2 Cytokines) Is Associated with Severe Forms of Respiratory Syncytial Virus BronchiolitisThe Journal of Infectious Diseases, 2001
- Rates of hospitalization for respiratory syncytial virus infection among children in MedicaidThe Journal of Pediatrics, 2000
- Purification and Characterization of the Respiratory Syncytial Virus Fusion ProteinJournal of General Virology, 1985
- Respiratory Syncytial Viral Infection in Infants with Congenital Heart DiseaseNew England Journal of Medicine, 1982
- AN EPIDEMIOLOGIC STUDY OF ALTERED CLINICAL REACTIVITY TO RESPIRATORY SYNCYTIAL (RS) VIRUS INFECTION IN CHILDREN PREVIOUSLY VACCINATED WITH AN INACTIVATED RS VIRUS VACCINEAmerican Journal of Epidemiology, 1969
- RESPIRATORY VIRUS IMMUNIZATIONAmerican Journal of Epidemiology, 1969